Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer

被引：3
作者：
Francini, Edoardo [1 ]
Petrioli, Roberto [3 ]
Fiaschi, Anna Ida [2 ]
Laera, Letizia [3 ]
Roviello, Giandomenico [3 ]
机构：
[1] Univ Rome, Policlin Umberto Hosp 1, Med Oncol Unit, Rome, Italy
[2] Univ Siena, Pharmacol Unit, I-53100 Siena, Italy
[3] Univ Siena, Med Oncol Unit, I-53100 Siena, Italy
来源：
MEDICINE | 2014年 / 93卷 / 27期
关键词：
INCREASED SURVIVAL; IMMUNOTHERAPY; MITOXANTRONE; PREDNISONE; CYP17;
D O I：
10.1097/MD.0000000000000163
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Prostate cancer is the second leading cause of cancer-related death in men in most Western countries. In this report, we present 2 cases of metastatic castration-resistant prostate cancer and chronic kidney disease. Both patients underwent and developed clinical resistance to androgen-deprivation therapy. Subsequently, the patients were treated with the conventional chemotherapeutic approach, which resulted in the worsening of renal function and performance status. Therefore, we opted for treatment with abiraterone acetate, and the patients exhibited improvements in renal function with good response of the disease.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
    Noonan, K. L.
    North, S.
    Bitting, R. L.
    Armstrong, A. J.
    Ellard, S. L.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1802 - 1807
  • [22] A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer
    McKay, Rana R.
    Werner, Lillian
    Jacobus, Susanna J.
    Jones, Xandra
    Mostaghel, Elahe A.
    Marck, Brett T.
    Choudhury, Atish D.
    Pomerantz, Mark M.
    Sweeney, Christopher J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    CANCER, 2019, 125 (04) : 524 - 532
  • [23] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
    Procopio, Giuseppe
    Grassi, Paolo
    Testa, Isabella
    Verzoni, Elena
    Torri, Valter
    Salvioni, Roberto
    Valdagni, Riccardo
    de Braud, Filippo
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 479 - 482
  • [24] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer
    Mckay, R. R.
    Werner, L.
    Fiorillo, M.
    Nakabayashi, M.
    Kantoff, P. W.
    Taplin, M-E
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) : 398 - 405
  • [25] Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate
    Fiala, Ondrej
    Hosek, Petr
    Korunkova, Hana
    Hora, Milan
    Kolar, Jiri
    Sorejs, Ondrej
    Topolcan, Ondrej
    Filipovsky, Jan
    Liska, Vaclav
    Santoni, Matteo
    Buti, Sebastiano
    Finek, Jindrich
    CANCER MEDICINE, 2024, 13 (01):
  • [26] Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors
    Romero, Miguel E. jimenez
    Gallego, Maria Camacho
    Serrato, Jose c. navarro
    Sanchez Hurtado, Miguel A.
    Santotoribio, Jose D.
    ANTICANCER RESEARCH, 2021, 41 (08) : 3955 - 3968
  • [27] Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Tolcher, A.
    Lee, P.
    Rosen, P. J.
    Kollmannsberger, C. K.
    Papadopoulos, K. P.
    Patnaik, A.
    Molina, A.
    Jiao, J.
    Pankras, C.
    Kaiser, B.
    Bernard, A.
    Tran, N.
    Acharya, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 237 - 244
  • [28] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [29] A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Ueda, Yujiro
    Matsubara, Nobuaki
    Takizawa, Itsuhiro
    Nishiyama, Tsutomu
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (08) : 774 - 779
  • [30] Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate
    Miyoshi, Yasuhide
    Uemura, Koichi
    Kawahara, Takashi
    Yoneyama, Shuko
    Hattori, Yusuke
    Teranishi, Jun-ichi
    Ohta, Jun-ichi
    Takebayashi, Shigeo
    Yokomizo, Yumiko
    Hayashi, Narihiko
    Yao, Masahiro
    Uemura, Hiroji
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : 472 - 478
12345